Eli Lilly deal shows there is high-quality IP in China for foreign businesses that are prepared to search it out
Suzhou-based biopharmaceuticals firm Innovent Biologics has entered into an alliance with Eli Lilly & Co which will see its cancer therapies developed and marketed worldwide by the US company in a deal potentially worth upwards of $456 million.
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.